Evidence map›Paper›PMID 26520623›Full record

ArticleLeukemia research2015

Impact of telomere length on survival in classic and variant hairy cell leukemia.

Evgeny Arons, Hong Zhou, Daniel C Edelman, Allison Gomez, Seth M Steinberg, David Petersen, Yonghong Wang, Paul S Meltzer, Robert J Kreitman

Abstract readComparative Study
In one paragraph

Article in Leukemia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Evgeny AronsLaboratory of Molecular Biology, National Cancer Institute (NCI), NIH, United States.
Hong ZhouLaboratory of Molecular Biology, National Cancer Institute (NCI), NIH, United States.
Daniel C EdelmanCancer Genetics Branch, NCI, NIH, United States.
Allison GomezCancer Genetics Branch, NCI, NIH, United States.
Seth M SteinbergBiostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, 9000 Rockville Pike, 37/5124b, Bethesda, MD 20892-4255, United States.
David PetersenCancer Genetics Branch, NCI, NIH, United States.
Yonghong WangCancer Genetics Branch, NCI, NIH, United States.
Paul S MeltzerCancer Genetics Branch, NCI, NIH, United States.
Robert J KreitmanLaboratory of Molecular Biology, National Cancer Institute (NCI), NIH, United States. Electronic address: kreitmar@mail.nih.gov.

Funding

Development of Recombinant Toxins to Treat Hematologic MalignanciesZIABC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 2009 to 2025
$21.7M
Cancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9M
RECOMBINANT TOXINS FOR TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIESZ01BC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 1998 to 2008
$1.5M
Intramural NIH HHS Z01 BC010301Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Telomeres, which protect the ends of chromosomes, are shortened in several hematologic malignancies, often with adverse prognostic implications, but their effect on prognosis of classic and variant hairy cell leukemia (HCL and HCLv) has not been reported. HCL/HCLv genomic DNA from 46 patients was studied by PCR to determine the ratio of telomere to single copy gene number (T/S). T/S was unrelated to diagnosis of HCL or HCLv (p=0.27), but shorter T/S was associated with unmutated immunoglobulin rearrangements (p=0.033) and age above the median at diagnosis (p=0.017). Low T/S was associated with shorter overall survival from diagnosis (OS), particularly T/S <0.655 (p=0.0064, adjusted p=0.019). Shorter OS was also associated with presence of unmutated (p<0.0001) or IGHV4-34+ (p<0.0001) rearrangements, or increasing age (p=0.0002). Multivariable analysis with Cox modeling showed that short T/S along with either unmutated or IGHV4-34+ rearrangements remained associated with reduced OS (p=0.0071, p=0.0024, respectively) after age adjustment. While T/S is relatively long in HCL and the disease usually indolent with excellent survival, shortened telomeres in HCL/HCLv are associated with decreased survival. Shortened T/S could represent a risk factor needing further investigation/intervention to determine if non-chemotherapy treatment options, in addition to or instead of chemotherapy, might be particularly useful.

Indexed as

Telomere ShorteningAge FactorsAntimetabolites, AntineoplasticCombined Modality TherapyDNA, NeoplasmDrug Resistance, NeoplasmFemaleGene Rearrangement, B-Lymphocyte, Heavy ChainHumansImmunoglobulin Heavy ChainsImmunophenotypingKaplan-Meier EstimateLeukemia, Hairy CellLeukocyte CountMaleMiddle AgedAntimetabolites, AntineoplasticDNA, NeoplasmImmunoglobulin Heavy ChainsChromosomesDNA damageHairy cell leukemiaMolecular markerTelomere

Identifiers

PMID26520623
PMCPMC4661072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.